• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 2, 2017

View Archived Issues

Celgene, Agios Pharmaceuticals win FDA approval for IDH2-targeting Idhifa in AML

A new therapy for certain adults with relapsed or refractory acute myeloid leukemia (AML), developed by Celgene Corp. and Agios Pharmaceuticals Inc., has won earlier-than-expected FDA approval following a priority review. Read More

One shoe's already dropped as Janssen's RA drug steps into adcom

A look at the FDA's briefing document for Wednesday's Arthritis Advisory Committee (AAC) meeting suggests the other shoe could drop on Janssen Biotech Inc.'s sirukumab. Read More

Extended family: Series B relates $83.5M for vectors to Homology, near clinical

Homology Medicines Inc. CEO Arthur Tzianabos told BioWorld that the new $83.5 million in series B money should let the firm "move our lead program all the way through a phase I/II proof-of-concept trial" while edging toward the clinic with the AMEnDR (AAV-Mediated Editing by Direct Homologous Recombination) platform at the same time. Read More

Milestone makes ready for phase III with $55M series C

Milestone Pharmaceuticals Inc. collected its biggest raise to date, completing a $55 million series C led by Novo Holdings A/S that included new investors Forbion Capital Partners and funds managed by Tekla Capital Management. Read More

Invitae Corp. acquires Good Start and Combimatrix in combo stock, cash deal

Genetic information firm Invitae Corp. plans to acquire both Good Start Genetics Inc., a molecular diagnostic company for preimplantation and carrier testing of inherited diseases, and Combimatrix Corp., a prenatal and pediatric diagnostic company, putting itself at the front of the family genetics space. Read More

Good drugs for bad bugs: Startup Bugworks gets grant for superbug drug development

HONG KONG – To speed up biopharmaceutical research on fighting superbugs, the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) recently awarded grants to a number of biopharma firms, among them a 3-year-old startup aptly named Bugworks Research India Pvt. Ltd., which received $2.6 million. Read More

Regulatory front

The FDA finalized a 2013 draft guidance on developing new antibacterial drugs to treat serious bacterial diseases in patients with an unmet medical need. Read More

Financings

Innoviva Inc., of Brisbane, Calif., said it plans to offer $175 million of convertible senior notes due in 2025 in a private placement. The purchasers will also have a 30-day option to purchase up to an additional $17.5 million of the notes. Read More

Appointments and advancements

Oramed Pharmaceuticals Inc., of Jerusalem, named Simon Bruce vice president of medical affairs. Read More

Other news to note

MT Pharma America Inc., of Jersey City, N.J., changed its corporate name to Mitsubishi Tanabe Pharma America Inc. Read More

In the clinic

Amygdala Neurosciences Inc., of Palo Alto, Calif., said it started a phase Ib study testing co-administration of ANS-6637 and alcohol. Read More

Earnings

Incyte Corp., of Wilmington, Del., reported second-quarter sales of JAK inhibitor Jakafi (ruxolitinib) totaling $276 million, compared to $208 million for the same period in 2016. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe